Bain & Company, a top global management consultancy, and Trinity Life Sciences, a leader in global life sciences commercialization solutions, have announced a strategic partnership to bring together Bain’s extensive global experience across the life sciences value chain with Trinity’s deep technical expertise in biopharma and medtech. The partnership includes Bain & Company taking a minority investment in Trinity.
“The life sciences industry is fast growing and quickly evolving, requiring both breadth of experience and depth of expertise from its advisors,” said Tim van Biesen, the head of Bain & Company’s global Healthcare practice. “This partnership delivers best-in-class capabilities to serve our clients’ comprehensive needs. By focusing on all relevant levels of life sciences organizations, we deliver the most tailored support and curated solutions to the questions and details that matter to each. Together, we ensure projects are delivered smoothly from conception to execution.”
Recommended AI News: 1 in 3 Employees Do Not Understand the Importance of Cybersecurity at Work
This news follows a number of strategic moves from Trinity, including a partnership with Kohlberg & Co, announced last November, as well as a recent acquisition of D Cube Analytics to add extensive data science and digital transformation capabilities to its growing commercialization portfolio.
“This partnership feels like a perfect match as we continue to expand and deepen our client offerings,” said David Fitzhenry, CEO of Trinity Life Sciences. “It brings together both companies’ industry-leading life sciences experts, our advanced data and analytics services, and Bain’s expansive capabilities—in areas such as private equity, M&A, commercial excellence and digital transformation—to serve projects that rise to the C-suite agenda. We look forward to serving existing and new clients together with our truly differentiated offering.”
“The collaboration between Bain & Company and Trinity offers unparalleled breadth and depth in commercial strategy, powered by strong data analytics,” said Matt Jennings, operating partner of Kohlberg & Co and chairman of Trinity Life Sciences. “It strengthens both companies, giving them a unique value proposition as the most capable biopharma advisors in the industry.”
Recommended AI News: Data Sprawl Creating Risk for Organizations Worldwide as Personal App Use in Business Continues to Rise
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.